| Features: |
| Ormeloxifene (Centchroman) — Nonsteroidal selective estrogen receptor modulator (SERM) originally developed as a once-weekly oral contraceptive. Ormeloxifene exhibits tissue-selective estrogenic and anti-estrogenic effects, including strong anti-estrogenic activity in breast tissue and modulation of estrogen signaling in the endometrium. Drug class: Selective Estrogen Receptor Modulator (SERM) / nonsteroidal anti-estrogen / repurposed anticancer drug. Primary clinical uses: Oral contraception, mastalgia, fibroadenoma, and selected gynecologic disorders. Ormeloxifene has been used clinically in India for decades. Cancer relevance: Moderate to strong preclinical evidence with limited clinical evidence. Ormeloxifene has demonstrated antiproliferative, pro-apoptotic, anti-invasive, and antimetastatic effects in breast, ovarian, head-and-neck, pancreatic, prostate, and hematologic cancer models. Early clinical studies in advanced breast cancer also reported objective responses in a subset of patients. Typical mechanisms: Estrogen receptor signaling modulation; proliferation ↓; cell-cycle progression ↓; apoptosis ↑; BAX ↑; BCL2 ↓; caspase activation ↑; PI3K/AKT signaling ↓; MAPK/ERK signaling ↓; NF-kB signaling ↓; migration ↓; invasion ↓; EMT ↓. Mechanisms vary by tumor type and may include estrogen-receptor-independent effects. Estrogen receptor relevance: Ormeloxifene is a SERM rather than a pure estrogen receptor antagonist. Its effects are tissue-selective and should not be interpreted as universal ESR1/ESR2 inhibition. Pharmacokinetics: Ormeloxifene has a long elimination half-life, approximately 168 hours, supporting once-weekly contraceptive dosing. Recommended product classification: Drug — SERM / Repurposed Anticancer Drug. |
| 8846- | DIM, | ORM, | Diindolylmethane Promotes Metabolic Crisis and Enhances the Efficacy of Centchroman in Breast Cancer: A 1H NMR-Based Approach |
| - | vitro+vivo, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:497 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid